Nesiritide

What is Nesiritide?

Nesiritide is a recombinant human B-type natriuretic peptide (rhBNP) — a 32-amino-acid peptide with a 17-residue disulfide-linked ring whose primary sequence is identical to endogenous human BNP-32 secreted by the cardiac ventricles in response to wall stress. It is manufactured in Escherichia coli and was developed by Scios Inc. in California; FDA approved it under the brand name Natrecor in August 2001 for the intravenous treatment of acutely decompensated congestive heart failure in patients with dyspnea at rest or with minimal activity. Scios was acquired by Johnson & Johnson in 2003 and the drug was marketed by J&J's Janssen subsidiary thereafter. Nesiritide acts on the same natriuretic peptide receptors as endogenous BNP — primarily NPR-A — to raise intracellular cyclic GMP and produce balanced arterial and venous vasodilation, modest natriuresis and diuresis, and partial suppression of the renin-angiotensin-aldosterone and sympathetic systems. It is given by trained inpatient staff as a 2 mcg/kg IV bolus followed by a 0.01 mcg/kg/min infusion, typically for up to 48 hours in a monitored setting. It is the textbook example in modern cardiology of a drug whose post-approval evidence base ultimately reframed its clinical role.

What Nesiritide Is Investigated For

Nesiritide remains FDA-approved for the IV treatment of acute decompensated heart failure with rest dyspnea, but its clinical role today is narrow and shrinking. The pivotal VMAC trial (Publication Committee for the VMAC Investigators, JAMA 2002) supported approval by showing modest dyspnea improvement and pulmonary capillary wedge pressure reduction at 3 hours versus placebo and versus nitroglycerin. Two pooled meta-analyses by Sackner-Bernstein and colleagues in 2005 — one in Circulation reporting increased risk of worsening renal function, the other in JAMA reporting a numerically higher 30-day mortality — triggered an intense controversy, an FDA-convened expert panel, and a sharp drop in inpatient use documented by Hauptman and colleagues (JAMA 2006). The definitive answer came in the ASCEND-HF trial (O'Connor et al., NEJM 2011), which randomized 7,141 ADHF patients and found neither the harm signal alleged in 2005 nor a meaningful clinical benefit beyond a small dyspnea improvement. The ROSE-AHF trial (Chen et al., JAMA 2013) further refuted a renal-protective role for low-dose nesiritide. By the 2022 AHA/ACC/HFSA heart failure guideline, nesiritide is not given a class recommendation for routine ADHF management. Real-world utilization has collapsed, formularies have largely removed it, and the drug today functions chiefly as a historical and pedagogical reference point on how post-marketing evidence changes practice even when the original signal of harm was wrong.

History & Discovery

Nesiritide's story begins with the 1988 isolation of B-type natriuretic peptide by Sudoh, Kangawa, and Matsuo from porcine brain — initially named 'brain natriuretic peptide' for its tissue of discovery before later work showed that the cardiac ventricles, not the brain, are the dominant source in humans. Endogenous BNP rises sharply in heart failure as a counter-regulatory hormone promoting vasodilation, natriuresis, and RAAS suppression, and by the late 1990s the assay-based use of BNP and NT-proBNP as biomarkers was establishing itself in cardiology. Scios Inc. (Mountain View, California) developed recombinant human BNP-32 — produced in E. coli and sequence-identical to the mature endogenous peptide — as a therapeutic infusion for acute decompensated heart failure. The Phase 3 program centered on the Colucci et al. NEJM 2000 trial (intravenous nesiritide vs. placebo for decompensated CHF) and the pivotal VMAC trial (Vasodilation in the Management of Acute CHF, JAMA 2002), which compared nesiritide to nitroglycerin and placebo in 489 hospitalized patients and showed both a hemodynamic and a small but statistically significant 3-hour dyspnea benefit. The FDA approved nesiritide as Natrecor in August 2001 for IV treatment of acute decompensated heart failure in patients with rest dyspnea. Johnson & Johnson acquired Scios in 2003 and marketed the drug through its Janssen subsidiary; uptake was rapid and a substantial outpatient infusion-clinic market emerged in the United States in the early 2000s. The inflection point came in 2005. Jonathan Sackner-Bernstein and colleagues published two pooled analyses of the available randomized trials: a March 2005 Circulation paper reporting an increased risk of worsening renal function with nesiritide, followed by an April 2005 JAMA paper reporting a numerically higher 30-day mortality (relative risk 1.74). The papers prompted an FDA Cardiorenal Advisory Committee review in mid-2005, an Eric Topol NEJM editorial titled 'Nesiritide — not verified,' and a sharp drop in inpatient and outpatient use. Hauptman and colleagues (JAMA 2006) documented the rapid decline in U.S. hospital use of nesiritide in the months after the publications. Scios committed to a large definitive outcomes trial. That trial, ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure), led by Christopher O'Connor and Adrian Hernandez at the Duke Clinical Research Institute, randomized 7,141 patients across 30 countries and was reported in NEJM in July 2011. It showed no mortality difference, no excess of worsening renal function, and only a small non-significant dyspnea improvement. Topol's accompanying editorial — 'The lost decade of nesiritide' — captured the moment: the alleged harm signal was not real, but neither was a meaningful benefit. The ROSE-AHF trial in 2013 then specifically tested low-dose nesiritide for renal protection in ADHF with renal dysfunction and was negative. Real-world use of nesiritide never recovered. Johnson & Johnson gradually wound down active marketing in the late 2010s, and most U.S. centers removed nesiritide from routine ADHF order sets. The 2022 AHA/ACC/HFSA heart failure guideline does not include nesiritide among its preferred ADHF therapies. The drug remains FDA-approved and nominally on-market, but functions today primarily as a teaching case in pharmacovigilance — an instructive sequence in which approval based on short-term endpoints, a non-randomized safety signal, regulatory and academic response, and a definitive mega-trial together reshaped the clinical role of an approved medication.

How It Works

Nesiritide is a lab-made copy of the body's own B-type natriuretic peptide — the hormone that hearts release when they are stretched and overworked. Given as an IV infusion, it tells blood vessels to relax and signals the kidneys to push out a little extra salt and water, which together unload a struggling heart. The same hormonal signal also dampens stress hormones like adrenaline and aldosterone that push the heart even harder during a flare. The mechanism makes physiologic sense and produces real short-term hemodynamic effects, but in large trials it did not translate into longer survival or fewer rehospitalizations.

Nesiritide is recombinant human BNP-32, a 32-amino-acid peptide with the sequence Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His and a Cys10-Cys26 disulfide bond forming a 17-residue ring identical to mature endogenous human BNP-32. It is produced in E. coli and is sequence-identical, not analog-modified, to the endogenous hormone secreted by ventricular cardiomyocytes in response to wall stress. Mechanistically, nesiritide binds the natriuretic peptide receptor A (NPR-A, also called guanylyl cyclase A / NPR1), a single-transmembrane particulate guanylyl cyclase expressed on vascular smooth muscle, renal collecting duct and glomerular cells, adrenal zona glomerulosa cells, and elsewhere. Receptor binding activates the intracellular guanylyl cyclase domain, raising intracellular cyclic guanosine monophosphate (cGMP). cGMP then activates protein kinase G (PKG) and modulates cyclic nucleotide–gated ion channels and phosphodiesterases, producing the integrated downstream effects: arterial and venous vasodilation (the dominant hemodynamic effect, lowering both preload and afterload), natriuresis and diuresis through reduced sodium reabsorption in the medullary collecting duct and increased glomerular filtration via afferent arteriolar dilation and efferent constriction, suppression of renin release from the juxtaglomerular apparatus and aldosterone secretion from the zona glomerulosa, and partial suppression of the sympathetic nervous system. A second receptor, NPR-C (the clearance receptor), binds nesiritide and endogenous BNP and ANP without generating a cGMP signal; instead, NPR-C internalizes ligand for lysosomal degradation. Plasma clearance of nesiritide also occurs via neprilysin (neutral endopeptidase) cleavage and renal filtration, giving an effective elimination half-life of approximately 18 minutes — but the pharmacodynamic effect on blood pressure persists longer than the plasma drug concentration would suggest, contributing to the post-infusion hypotension occasionally seen. The mechanism is biologically coherent — endogenous BNP is itself a counter-regulatory response to volume overload — and produces measurable short-term reductions in pulmonary capillary wedge pressure, systemic vascular resistance, and self-reported dyspnea in ADHF, as documented in the VMAC trial. The unresolved question, ultimately answered by ASCEND-HF, was whether augmenting an endogenous compensatory signal with a pharmacologic infusion could translate hemodynamic benefit into a durable clinical outcome — and the answer, in the largest randomized trial of an ADHF therapy ever conducted at the time, was essentially no.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Nesiritide:

• 01Whether any specific ADHF subgroup — defined by phenotype, biomarker, or hemodynamic profile — derives clinically meaningful benefit from nesiritide that was diluted in the heterogeneous ASCEND-HF population remains unresolved and is unlikely to be prospectively addressed.
• 02Long-term outcomes (90-day, 1-year mortality and rehospitalization) of patients who received nesiritide are reasonably characterized but have not been re-examined in the modern era of SGLT2 inhibitors, sacubitril/valsartan, and contemporary diuretic strategies.
• 03The interaction between nesiritide and chronic neprilysin-inhibitor therapy (sacubitril/valsartan) is mechanistically interesting but clinically untested — nesiritide is a neprilysin substrate, and patients on chronic neprilysin inhibitors might have prolonged drug exposure.
• 04Whether closely related natriuretic peptide therapeutics (cenderitide, ularitide, carperitide, designer chimeric peptides) can rescue the therapeutic premise that nesiritide failed to fulfill remains unsettled — ularitide's TRUE-AHF trial was likewise neutral on outcomes.
• 05Real-world utilization data after 2015 are sparse; how many U.S. hospitals retain nesiritide on formulary and how many actively use it is not well characterized in the public literature.

Forms & Administration

Nesiritide is supplied as a sterile lyophilized powder for intravenous use, reconstituted and diluted before administration by trained inpatient cardiology or critical-care staff. The FDA-labeled regimen is a 2 mcg/kg IV bolus over approximately 60 seconds, followed immediately by a continuous infusion of 0.01 mcg/kg/min, typically continued for up to 48 hours. Continuous blood pressure monitoring is required because dose-dependent symptomatic hypotension is the dominant adverse effect. The bolus may be omitted in patients at heightened hypotension risk, and the infusion may be reduced to 0.005 mcg/kg/min if hypotension develops. There is no oral, subcutaneous, intramuscular, or outpatient formulation — nesiritide is a hospital-only intravenous agent, never appropriate for self-administration or non-monitored use. It is a prescription drug administered exclusively under direct physician supervision in a monitored hospital setting.

Common Questions

Who Nesiritide Is NOT For

Drug & Supplement Interactions

The clinically important interactions are pharmacodynamic rather than pharmacokinetic. Concurrent intravenous vasodilators — particularly nitroglycerin and sodium nitroprusside — substantially increase the risk of symptomatic hypotension and should generally be avoided or cross-tapered with very close blood pressure monitoring. ACE inhibitors and angiotensin receptor blockers also potentiate hypotension; in ASCEND-HF, baseline ACEi/ARB use was common and did not preclude nesiritide use, but added vigilance is appropriate. Concomitant diuretic therapy (loop diuretics) is the rule rather than the exception in ADHF, and the combination is generally well tolerated, though attention to volume status reduces hypotension risk. Theoretical interactions with neprilysin inhibitors (sacubitril/valsartan) are notable: neprilysin is one of the enzymes that degrades nesiritide, so co-administration could prolong nesiritide's pharmacodynamic effect, but formal interaction data are sparse and the contemporary scenario in which a patient is simultaneously on chronic sacubitril/valsartan and inpatient nesiritide is uncommon. Nesiritide does not undergo cytochrome P450 metabolism and has no documented CYP-mediated drug interactions.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions